Oncotarget

Research Papers:

Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis

Madison Black, Ivraym B. Barsoum, Peter Truesdell, Tiziana Cotechini, Shannyn K. Macdonald-Goodfellow, Margaret Petroff, D. Robert Siemens, Madhuri Koti, Andrew W.B. Craig, Charles H. Graham _

PDF  |  HTML  |  Supplementary Files  |  Order a Reprint

Oncotarget. 2016; 7:10557-10567. https://doi.org/10.18632/oncotarget.7235

Metrics: PDF 2843 views  |   HTML 1640 views  |   ?  


Abstract

Madison Black1, Ivraym B. Barsoum1,2, Peter Truesdell1,4, Tiziana Cotechini1, Shannyn K. Macdonald-Goodfellow1, Margaret Petroff3, D. Robert Siemens1,2, Madhuri Koti1,4, Andrew W.B. Craig1,4 and Charles H. Graham1,2,4

1 Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, Ontario, Canada

2 Department of Urology, Queen’s University, Kingston, Ontario, Canada

3 Department of Pathobiology and Diagnostic Investigation, Michigan State University, East Lansing, Michigan, USA

4 Cancer Biology and Genetics, Queen’s Cancer Research Institute, Kingston, Ontario, Canada

Correspondence to:

Charles H. Graham, email:

Keywords: PD-1, PD-L1, chemoresistance, immune escape, metastasis

Received: December 04, 2015 Accepted: January 25, 2016 Published: February 07, 2016

Abstract

The ability of tumor cells to avoid immune destruction (immune escape) as well as their acquired resistance to anti-cancer drugs constitute important barriers to the successful management of cancer. Interaction between the Programmed Death Ligand 1 (PD-L1) on the surface of tumor cells with the Programmed Death-1 (PD-1) receptor on cytotoxic T lymphocytes leads to inactivation of these immune effectors and, consequently, immune escape. Here we show that the PD-1/PD-L1 axis also leads to tumor cell resistance to conventional chemotherapeutic agents. Using a panel of PD-L1-expressing human and mouse breast and prostate cancer cell lines, we found that incubation of breast and prostate cancer cells in the presence of purified recombinant PD-1 resulted in resistance to doxorubicin and docetaxel as determined using clonogenic survival assays. Co-culture with PD-1-expressing Jurkat T cells also promoted chemoresistance and this was prevented by antibody blockade of either PD-L1 or PD-1 or by silencing of the PD-L1 gene. Moreover, inhibition of the PD-1/PD-L1 axis using anti-PD-1 antibody enhanced doxorubicin chemotherapy to inhibit metastasis in a syngeneic mammary orthotopic mouse model of metastatic breast cancer. To further investigate the mechanism of tumor cell survival advantage upon PD-L1 ligation, we show that exposure to rPD-1 promoted ERK and mTOR growth and survival pathways leading to increased cell proliferation. Overall, the findings of this study indicate that combinations of chemotherapy and immune checkpoint blockade may limit chemoresistance and progression to metastatic disease.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 7235